Rho GTPase effectors and NAD metabolism in cancer immune suppression
- PMID: 29207896
- PMCID: PMC6056002
- DOI: 10.1080/14728222.2018.1413091
Rho GTPase effectors and NAD metabolism in cancer immune suppression
Abstract
Sustained proliferative signaling and de-regulated cellular bioenergetics are two of the chief hallmarks of cancer. Alterations in the Ras pathway and its downstream effectors are among the major drivers for uncontrolled cell growth in many cancers. The GTPases are one of the signaling molecules that activate crucial signal transducing pathways downstream of Ras through several effector proteins. The GTPases (GTP bound) interact with several effectors and modulate a number of different biological pathways including those that regulate cytoskeleton, cellular motility, cytokinesis, proliferation, apoptosis, transcription and nuclear signaling. Similarly, the altered glycolytic pathway, the so-called 'Warburg effect', rewires tumor cell metabolism to support the biosynthetic requirements of uncontrolled proliferation. There exists strong evidence for the critical role of the glycolytic pathway's rate limiting enzymes in promoting immunosuppression. Areas covered: We review the emerging roles of GTPase effector proteins particularly the p21 activated kinase 4 (PAK4) and nicotinamide biosynthetic pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT) as signaling molecules in immune surveillance and the immune response. Expert opinion: In this expert opinion article we highlight the recent information on the role of GTPases and the metabolic enzymes on the immune microenvironment and propose some unique immune therapeutic opportunities.
Keywords: GTPase; NAD; NAMPT; NAMPT inhibitor; NAPRT; P21 activated kinases; PAK4; PAK4 inhibitor; PD-1; PD-L1; Ras; immune checkpoint.
Figures


Similar articles
-
Rho-GTPases as key regulators of T lymphocyte biology.Small GTPases. 2014;5:e28208. doi: 10.4161/sgtp.28208. Epub 2014 May 8. Small GTPases. 2014. PMID: 24825161 Free PMC article. Review.
-
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.Expert Rev Anticancer Ther. 2016 Aug;16(8):827-38. doi: 10.1080/14737140.2016.1190649. Epub 2016 Jul 5. Expert Rev Anticancer Ther. 2016. PMID: 27186719 Review.
-
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.Cell Metab. 2021 Jan 5;33(1):110-127.e5. doi: 10.1016/j.cmet.2020.10.021. Epub 2020 Nov 9. Cell Metab. 2021. PMID: 33171124
-
RHO GTPases: from new partners to complex immune syndromes.Nat Rev Immunol. 2021 Aug;21(8):499-513. doi: 10.1038/s41577-021-00500-7. Epub 2021 Feb 5. Nat Rev Immunol. 2021. PMID: 33547421 Review.
-
Chemical inhibition through conformational stabilization of Rho GTPase effectors.Handb Exp Pharmacol. 2008;(186):431-60. doi: 10.1007/978-3-540-72843-6_18. Handb Exp Pharmacol. 2008. PMID: 18491063 Review.
Cited by
-
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy.Cancers (Basel). 2020 Jul 2;12(7):1757. doi: 10.3390/cancers12071757. Cancers (Basel). 2020. PMID: 32630618 Free PMC article.
-
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy.Front Oncol. 2020 Jan 17;9:1514. doi: 10.3389/fonc.2019.01514. eCollection 2019. Front Oncol. 2020. PMID: 32010616 Free PMC article. Review.
-
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2. Cancer Immunol Immunother. 2023. PMID: 36729213 Free PMC article.
-
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations.JCO Oncol Adv. 2025 May 2;2(1):e2400032. doi: 10.1200/OA-24-00032. eCollection 2025. JCO Oncol Adv. 2025. PMID: 40330142 Free PMC article.
-
Single-cell transcriptomics in colorectal cancer uncover the potential of metastasis and immune dysregulation of a cell cluster overexpressed PRSS22.Front Immunol. 2025 May 20;16:1586428. doi: 10.3389/fimmu.2025.1586428. eCollection 2025. Front Immunol. 2025. PMID: 40463392 Free PMC article.
References
-
- Lv J, Wang J, Chang S, et al. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism? Acta Biochim Biophys Sin (Shanghai) 2016;48:17–26. - PubMed
-
- Jansen S, Gosens R, Wieland T, et al. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther. 2017 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous